H.C. Wainwright lowered the firm’s price target on Assertio Holdings (ASRT) to $3.50 from $4 and keeps a Buy rating on the shares following the Q4 report. The firm says the company reported “lukewarm” 2025 sales guidance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT:
- Assertio Therapeutics: Strategic Growth and Financial Resilience Amidst Market Volatility
- Assertio price target lowered to $1.75 from $2.15 at Alliance Global
- Assertio Therapeutics’ Earnings Call: Growth Amid Challenges
- Assertio Therapeutics Reports 2024 Financial Results
- ASRT Earnings Report this Week: Is It a Buy, Ahead of Earnings?